(NASDAQ: KURA) Kura Oncology's forecast annual revenue growth rate of 85.88% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.66%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.47%.
Kura Oncology's revenue in 2026 is $67,482,000.On average, 17 Wall Street analysts forecast KURA's revenue for 2026 to be $13,353,692,966, with the lowest KURA revenue forecast at $5,340,947,208, and the highest KURA revenue forecast at $29,836,909,293. On average, 15 Wall Street analysts forecast KURA's revenue for 2027 to be $17,177,488,233, with the lowest KURA revenue forecast at $4,599,065,562, and the highest KURA revenue forecast at $48,691,779,649.
In 2028, KURA is forecast to generate $43,108,455,582 in revenue, with the lowest revenue forecast at $7,851,278,958 and the highest revenue forecast at $186,640,780,767.